<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936805</url>
  </required_header>
  <id_info>
    <org_study_id>2173862</org_study_id>
    <nct_id>NCT01936805</nct_id>
  </id_info>
  <brief_title>ROsuvastatin LOading and Clinical Outcomes Trial</brief_title>
  <acronym>ROLOCO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Yuksek Ihtisas Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuksek Ihtisas Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to evaluate the effect of pre-procedural single high
      loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and
      composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel
      revascularization (TVR), or stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>all cause death and composite of death or myocardial infarction from CV causes, TVR, or stroke</measure>
    <time_frame>4 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>4 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of death or myocardial infarction from CV causes, TVR, or stroke</measure>
    <time_frame>4 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A loading dose of placebo was administrated 24 h before the PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  statin-naive patients

          -  stable ischemic heart disease

          -  de novo lesions appropriate for PCI

        Exclusion Criteria:

          -  current statin use

          -  statin allergic patients

          -  acute coronary syndromes

          -  lesions not appropriate for PCI

          -  refusal for participation

          -  statin quitting during follow- up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yuksek Ihtisas Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Altindag</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 2, 2013</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yuksek Ihtisas Hospital</investigator_affiliation>
    <investigator_full_name>Serkan Cay</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
